Elbasvir-Grazoprevir Zepatier
Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ribavirin Copegus, Rebetol, Ribasphere
Sofosbuvir Sovaldi
Sofosbuvir-Velpatasvir Epclusa
Sofosbuvir-Velpatasvir-Voxilaprevir VoseviSelf-StudyTreatment of Hepatitis C Infection
Treatment of Hepatitis C
Sign In or Register to get started
Treatment of Hepatitis C
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 2 Overview
Retreatment of Patients with Prior HCV Treatment Experience - 0%Topic 1
IntroductionActivities- 0%Topic 2
Special Considerations with RetreatmentActivities- 0%Topic 3
Treatment Failure with Sofosbuvir-Containing DAA or Elbasvir-GrazoprevirActivities- 0%Topic 4
Treatment Failure with Glecaprevir-PibrentasvirRetreatment of Patients with Prior HCV Treatment Experience Overview
About this Lesson
Last Updated: September 19th, 2023CNE/CME Continuing Education
This lesson qualifies for:- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour and 1 CE contact hour (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: November 1st, 2023CNE and CME Expiration: October 31st, 2026 (4th Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
1Quiz
Score 80%+2Give Feedback
Complete survey3Print CE Certificate
Obtain proof of CE4th Edition
First appearance. This Lesson did not appear in the previous edition.Learning Objectives
- Discuss the approach to retreatment of patients with chronic hepatitis C in the direct-acting antiviral (DAA) era
- List the preferred therapeutic combinations for retreatment in persons with prior sofosbuvir-containing regimens
- Describe recommended options for retreatment in persons with prior treatment with elbasvir-grazoprevir
- Review preferred retreatment options for persons with prior treatment with glecaprevir-pibrentasvir
- Summarize options for persons with multiple prior DAA treatment failures
Lesson Contributors
Authors
H. Nina Kim, MD, MScH. Nina Kim, MD, MSc
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneMaria A. Corcorran, MD, MPHMaria A. Corcorran, MD, MPH
Assistant Professor
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneReviewers
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
- 0%Topic 2
Funded by
Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS21-2105)
Created at
University of Washington
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE provided byUniversity of Washington School of Nursing
Copyright © 2024 Hepatitis C Online
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhcvc-master-c8843673-2024-11-13-205624